89bio developed pegozafermin, a glycoPEGylated fibroblast growth factor 21 (FGF21) analog, for patients with liver and cardiometabolic diseases. The candidate was in Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, including compensated cirrhosis, and for severe hypertriglyceridemia. Its extended half-life and combined anti-fibrotic and anti-inflammatory mechanism were designed to improve efficacy and tolerability in moderate to severe disease.
89bio focused on patients with advanced liver fibrosis and severe hypertriglyceridemia who lacked effective treatment options. The company advanced pegozafermin for MASH, a progressive form of fatty liver disease closely linked to obesity and type 2 diabetes. It also explored the drug's use in cardiovascular and metabolic conditions where FGF21 biology could complement existing therapies.
